N Adra1, S K Althouse1, H Liu1, M J Brames1, N H Hanna1, L H Einhorn1, C Albany2. 1. Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA. 2. Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA calbany@iu.edu.
Abstract
BACKGROUND: Based on the risk stratification from the International Germ Cell Cancer Collaborative Group (IGCCCG), only 14% of patients with metastatic germ-cell tumors (GCT) had poor-risk disease with a 5-year progression-free survival (PFS) rate of 41% and a 5-year overall survival (OS) rate of only 48%. This analysis attempts to identify prognostic factors for patients with poor-risk disease. PATIENTS AND METHODS: We conducted a retrospective analysis of all patients with GCT diagnosed and treated at Indiana University from 1990 to 2014. Clinical and pathological characteristics were available for all patients and all of them were treated with cisplatin-etoposide-based chemotherapy. Cox proportional hazards models were used to target significant predictors of disease progression and mortality. A significance level of 5% was used in the analysis. RESULTS: We identified 273 consecutive patients with poor-risk GCT (PRGCT). Median follow-up time was 8 years (range 0.03-24.5). The 5-year PFS and OS rates were 58% [95% confidence interval (CI) 51% to 63%] and 73% (95% CI 67% to 78%), respectively. In multivariate survival analyses, multiple risk factors were associated with disease progression, including liver metastasis, brain metastasis, primary mediastinal nonseminomatous GCT (PMNSGCT), and elevation in logarithmic β-hCG. Significant predictors of mortality were PMNSGCT [hazard ratio (HR) 4.63, 95% CI 2.25-9.56; P < 0.001], brain metastasis (HR 3.30, 95% CI 1.74-6.23; P < 0.001), and increasing age (HR 1.03, 95% CI 1.01-1.06; P = 0.02). CONCLUSIONS: Patients with PMNSGCT, brain metastasis, or with increasing age are at higher risk of death than their counterparts. This contemporary cohort (1990-2014) of 273 patients with PRGCT had improved PFS and OS outcomes than those from the historical IGCCCG group of patients (1975-1990).
BACKGROUND: Based on the risk stratification from the International Germ Cell Cancer Collaborative Group (IGCCCG), only 14% of patients with metastatic germ-cell tumors (GCT) had poor-risk disease with a 5-year progression-free survival (PFS) rate of 41% and a 5-year overall survival (OS) rate of only 48%. This analysis attempts to identify prognostic factors for patients with poor-risk disease. PATIENTS AND METHODS: We conducted a retrospective analysis of all patients with GCT diagnosed and treated at Indiana University from 1990 to 2014. Clinical and pathological characteristics were available for all patients and all of them were treated with cisplatin-etoposide-based chemotherapy. Cox proportional hazards models were used to target significant predictors of disease progression and mortality. A significance level of 5% was used in the analysis. RESULTS: We identified 273 consecutive patients with poor-risk GCT (PRGCT). Median follow-up time was 8 years (range 0.03-24.5). The 5-year PFS and OS rates were 58% [95% confidence interval (CI) 51% to 63%] and 73% (95% CI 67% to 78%), respectively. In multivariate survival analyses, multiple risk factors were associated with disease progression, including liver metastasis, brain metastasis, primary mediastinal nonseminomatous GCT (PMNSGCT), and elevation in logarithmic β-hCG. Significant predictors of mortality were PMNSGCT [hazard ratio (HR) 4.63, 95% CI 2.25-9.56; P < 0.001], brain metastasis (HR 3.30, 95% CI 1.74-6.23; P < 0.001), and increasing age (HR 1.03, 95% CI 1.01-1.06; P = 0.02). CONCLUSIONS:Patients with PMNSGCT, brain metastasis, or with increasing age are at higher risk of death than their counterparts. This contemporary cohort (1990-2014) of 273 patients with PRGCT had improved PFS and OS outcomes than those from the historical IGCCCG group of patients (1975-1990).
Authors: Stuart Hinton; Paul J Catalano; Lawrence H Einhorn; Craig R Nichols; E David Crawford; Nicholas Vogelzang; Donald Trump; Patrick J Loehrer Journal: Cancer Date: 2003-04-15 Impact factor: 6.860
Authors: J T Hartmann; L Einhorn; C R Nichols; J P Droz; A Horwich; A Gerl; S D Fossa; J Beyer; J Pont; H J Schmoll; L Kanz; C Bokemeyer Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: A Necchi; S Lo Vullo; G Rosti; M Badoglio; P Giannatempo; D Raggi; S Secondino; L Mariani; F Lanza; P Pedrazzoli Journal: Bone Marrow Transplant Date: 2017-06-05 Impact factor: 5.483
Authors: C Albany; N Adra; A C Snavely; C Cary; T A Masterson; R S Foster; K Kesler; T M Ulbright; L Cheng; M Chovanec; F Taza; K Ku; M J Brames; N H Hanna; L H Einhorn Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Jiaqi Zhang; Yeye Chen; Lei Liu; Mengxin Zhou; Cheng Huang; Chao Guo; Shanqing Li Journal: Cancer Manag Res Date: 2021-11-13 Impact factor: 3.989
Authors: Michal Chovanec; Zuzana Cierna; Viera Miskovska; Katarina Machalekova; Katarina Kalavska; Katarina Rejlekova; Daniela Svetlovska; Dusan Macak; Stanislav Spanik; Karol Kajo; Pavel Babal; Michal Mego; Jozef Mardiak Journal: BMC Cancer Date: 2018-11-03 Impact factor: 4.430
Authors: Fadi Taza; Michal Chovanec; Anna Snavely; Nasser H Hanna; Clint Cary; Timothy A Masterson; Richard S Foster; Lawrence H Einhorn; Costantine Albany; Nabil Adra Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544